Medeor Life Care LLP Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Medeor Life Care LLP Pharmaceutical Export Portfolio Dataset — 2 Products, $3.9M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Medeor Life Care LLP — Pharmaceutical Exporter Profile (2026) | 2 Products, $3.9M Trade | TransData Nexus

Medeor Life Care LLP

Indian Pharmaceutical Exporter · Diabetes & Endocrine Specialist · $3.9M Total Trade · DGFT Verified

Medeor Life Care LLP is an Indian pharmaceutical exporter with a total trade value of $3.9M across 2 products in 2 therapeutic categories. Based on 82 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Metformin ($3.6M), Ornidazole ($220.9K), .

Medeor Life Care LLP — Export Portfolio & Destination Treemap

Medeor Life Care LLP pharmaceutical export portfolio — 2 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Medeor Life Care LLP? — Company Overview & Market Position

Medeor Life Care LLP is a pharmaceutical enterprise established on June 29, 2015, in Gurgaon, Haryana, India. Founded by two experienced pharmaceutical specialists, the company aims to serve the international pharmaceutical industry by providing guidance in establishing pharmaceutical businesses across various countries and exporting quality finished formulations.

The company operates as a limited liability partnership (LLP) under the Corporate Identification Number (CIN) AAE-2733. As of March 31, 2024, Medeor Life Care LLP reported a total obligation of contribution of ₹1.50 crore. The firm's registered office is located at J-172, Cedar Crest Nirvana Country, Sector-50, Gurgaon, Haryana, 122003, India.

Medeor Life Care LLP specializes in the export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's product portfolio spans various therapeutic categories, such as gastrointestinal, cardiovascular, anti-diabetics, pain management, antibiotics, and respiratory treatments.

What Does Medeor Life Care LLP Export? — Product Portfolio Analysis

Top Products by Export Value

1Metformin$3.6M

Product Portfolio — Top 2 by Export Value

Medeor Life Care LLP exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Metformin	Diabetes & Endocrine	$3.6M	73	0.8%	2
2	Ornidazole	Advanced Antibiotics	$220.9K	9	1.3%	8

Medeor Life Care LLP exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $3.9M. The top category is Diabetes & Endocrine (94.3% of portfolio), followed by Advanced Antibiotics (5.7%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Medeor Life Care LLP — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Medeor Life Care LLP collaborates with high-quality manufacturing units in India and abroad to supply a diverse range of finished pharmaceutical formulations. These formulations include oral solid dosage forms (tablets and capsules), suppositories, pessaries, liquids in the form of syrups and suspensions, and injectables such as infusions (LVP and SVP) and dry powder injections.

3Key Leadership

The leadership team of Medeor Life Care LLP comprises:

Swati Nagpal: Designated Partner
Rajiv Bedi: Designated Partner
Poonam Gupta: Designated Partner

These individuals play pivotal roles in steering the company's strategic direction and operations.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Medeor Life Care LLP Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Medeor Life Care LLP's export activities are primarily focused on markets in Africa, Latin America, and Southeast Asia. The company's trade data indicates shipments to countries such as Burundi, Myanmar, and Azerbaijan. While specific regulatory approvals in the US, EU, UK, Australia, and Japan are not detailed in the available sources, the company's established presence in various international markets suggests compliance with relevant regulatory standards.

2Emerging Markets

Medeor Life Care LLP has made significant inroads into emerging markets, particularly in Africa and Southeast Asia. The company's export data highlights shipments to countries like Burundi, Myanmar, and Azerbaijan. These markets often require adherence to specific regulatory standards, such as WHO prequalification, to ensure product quality and safety. While the company's certifications are not explicitly detailed in the available sources, its active engagement in these regions suggests a commitment to meeting international regulatory requirements.

3Geographic Strategy

Medeor Life Care LLP's export strategy demonstrates a focused approach, with a significant concentration on the Diabetes & Endocrine therapeutic category, accounting for 94.3% of its total export value. This specialization indicates a strategic emphasis on addressing the global demand for anti-diabetic medications. The company's portfolio concentration, with its top five products comprising 100% of its exports, suggests a targeted product strategy aimed at maximizing impact within its chosen therapeutic area.

Medeor Life Care LLP — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Medeor Life Care LLP's interactions with the U.S. Food and Drug Administration (FDA), including facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history, are not available in the provided sources. This lack of information may indicate that the company does not currently export to the U.S. market or has not pursued FDA approvals for its products.

2WHO & EU GMP

The available information does not specify whether Medeor Life Care LLP holds World Health Organization (WHO) prequalification or European Union Good Manufacturing Practice (EU GMP) certifications. These certifications are crucial for accessing certain international markets and ensuring product quality. The company's active engagement in various global markets suggests a potential commitment to obtaining such certifications, but explicit confirmation is lacking.

3CDSCO & Indian Regulatory

Medeor Life Care LLP operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company's manufacturing licenses, approvals from state drug controllers, and export No Objection Certificates (NOCs) are not detailed in the available sources. However, the company's established presence in the pharmaceutical export sector implies compliance with Indian regulatory requirements.

Medeor Life Care LLP — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

In the therapeutic category of anti-diabetics, Medeor Life Care LLP faces competition from several established pharmaceutical companies. While specific market share data is not available, the company's focus on this segment positions it among key players in the global anti-diabetic market. The company's export data indicates shipments to countries such as Burundi, Myanmar, and Azerbaijan, suggesting a competitive presence in emerging markets.

2Key Differentiators

Medeor Life Care LLP's key differentiators include its specialized focus on the anti-diabetic segment, which constitutes the majority of its export value. The company's ability to establish strong ties with high-quality manufacturing units in India and abroad enables it to offer a diverse range of finished pharmaceutical formulations. Additionally, its experience in turning around non-profitable operations into profit-oriented entities demonstrates a robust operational strategy.

3Strategic Position

Medeor Life Care LLP's current strategic direction centers on the export of finished pharmaceutical formulations, with a particular emphasis on anti-diabetic products. The company's active engagement in various international markets, including emerging regions, reflects a strategy aimed at global expansion. Future outlooks would benefit from the company's potential pursuit of international certifications and regulatory approvals to enhance its market presence.

Buyer Due Diligence Brief — Evaluating Medeor Life Care LLP as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Medeor Life Care LLP has demonstrated a consistent track record in exporting pharmaceutical products, with a total export value of $3.9 million USD and 82 shipments recorded between 2022 and 2026. The company's portfolio concentration, with its top five products comprising 100% of its exports, indicates a focused and reliable supply chain. The absence of publicly available records of regulatory issues further underscores the company's reliability as a supplier.

2Certifications to Verify

Importers should verify the following certifications when considering products from Medeor Life Care LLP:

FDA Registration: Confirm the company's registration status with the U.S. Food and Drug Administration.
WHO Prequalification: Verify if the company's products are prequalified by the World Health Organization.
EU GMP Certification: Check for compliance with European Union Good Manufacturing Practice standards.

Frequently Asked Questions — Medeor Life Care LLP

How many pharmaceutical products does Medeor Life Care LLP export from India?

Medeor Life Care LLP exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Metformin ($3.6M), Ornidazole ($220.9K). Total export value is $3.9M.

What is Medeor Life Care LLP's total pharmaceutical export value?

Medeor Life Care LLP's total pharmaceutical export value is $3.9M, based on 82 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Medeor Life Care LLP cover?

Medeor Life Care LLP exports across 2 therapeutic categories. The largest are Diabetes & Endocrine (94.3%, 1 products), Advanced Antibiotics (5.7%, 1 products).

Get Full Medeor Life Care LLP Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.